RxDoctor Payments Data

Margaret Hennessey

Family · Olympia, WANPI 1225328248

Payments from drug & device makers

$960in general payments, 2019–2025

Across 40 payments — averaging $24.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$394
  • Novo Nordisk$232
  • AstraZeneca$59
  • AbbVie$52
  • Johnson & Johnson$43
  • Boehringer Ingelheim$31
  • plus $149 from 7 others

What the payments were for

  • Food & beverage$960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$960 in reported general payments places this provider in the 80th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$54,257
Medicare patients
115
Services billed
634

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide86$92,044
MounjaroTirzepatide52$58,394
EliquisApixaban30$43,002
JardianceEmpagliflozin22$23,454
XareltoRivaroxaban16$11,275
Bydureon BciseExenatide Microspheres13$8,241
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$4,109
Estradiol53$3,091
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen76$2,893
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen36$2,314
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,117
Gabapentin93$1,767
Levothyroxine Sodium220$1,654
Losartan Potassium138$1,459
Rosuvastatin Calcium101$1,380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$232$92,04486 claims
Lilly USA, LLCMounjaro$394$58,39452 claims
PfizerEliquis$21$43,00230 claims
Boehringer IngelheimJardiance$31$23,45422 claims
Johnson & JohnsonXarelto$43$11,27516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,706 family providers in Washington.

Other family in Olympia

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →